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Abstract
Background: Red cell distribution width (RDW), a classical parameter used in the differential diagnosis of anemia,
has recently been recognized as a marker of chronic inflammation and high levels of oxidative stress (OS). Fanconi
anemia (FA) is a genetic disorder associated to redox imbalance and dysfunctional response to OS. Clinically, it is
characterized by progressive bone marrow failure, which remains the primary cause of morbidity and mortality.
Macrocytosis and increased fetal hemoglobin, two indicators of bone marrow stress erythropoiesis, are generally the
first hematological manifestations to appear in FA. However, the significance of RDW and its possible relation to
stress erythropoiesis have never been explored in FA. In the present study we analyzed routine complete blood
counts from 34 FA patients and evaluated RDW, correlating with the hematological parameters most consistently
associated with the FA phenotype.
Results: We showed, for the first time, that RDW is significantly increased in FA. We also showed that increased
RDW is correlated with thrombocytopenia, neutropenia and, most importantly, highly correlated with anemia.
Analyzing sequential hemograms from 3 FA patients with different clinical outcomes, during 10 years follow-up, we
confirmed a consistent association between increased RDW and decreased hemoglobin, which supports the
postulated importance of RDW in the evaluation of hematological disease progression.
Conclusions: This study shows, for the first time, that RDW is significantly increased in FA, and this increment is
correlated with neutropenia, thrombocytopenia, and highly correlated with anemia. According to the present
results, it is suggested that increased RDW can be a novel marker of stress erythropoiesis in FA.
Keywords: Fanconi anemia (FA), Red cell distribution width (RDW), Stress erythropoiesis, Bone marrow failure (BMF),
Oxidative stress (OS)
Background
Red cell distribution width (RDW) is a simple
hematological parameter routinely obtained in standard
complete blood cell counts, being currently used in the
differential diagnosis of anemia. Increased RDW, indicat-
ing the presence of anisocytosis, has been associated to
iron deficiency and nutritional deficiencies (folate or
vitamin B12) and to a large number of disorders such as
cardiovascular disease, venous thromboembolism, can-
cer, diabetes, community-acquired pneumonia, liver and
kidney failure and chronic obstructive pulmonary disease
[1]. This comprehensive clinical spectrum makes RDW a
parameter with an importance far beyond the differential
diagnosis of anemia.
Increased RDW appears as a consequence of deregula-
tion of red blood cells (RBC) homeostasis, involving
both impaired erythropoiesis and RBC degradation, and
it was recently recognized as a marker of both chronic
inflammation and high levels of oxidative stress (OS) [2].
In fact, increased RDW was already related to high levels
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of pro-inflammatory cytokines, such as tumor necrosis
factor α and interleukin 6 [3], high levels of OS-induced
RBC damage and shortened RBC survival [4].
Fanconi anemia (FA), the most frequent form of inher-
ited bone marrow failure (BMF), is a recessive/X linked
disorder caused by biallelic mutations in one of the 19
FA genes so far characterized [5] that function in a com-
mon signaling pathway that controls the maintenance of
genomic stability: the FA/BRCA pathway. The FA clin-
ical manifestations are heterogeneous, although generally
patients progress to BMF which, unless treated, remains
the primary cause of morbidity and mortality [6], with
patients suffering from early development of cancer, par-
ticularly acute myeloid leukemia (AML). At cellular level
FA is characterized by chromosome instability (CI) and
dysfunctional response to OS. CI is the hallmark of FA,
being the hypersensitivity of FA cells to the clastogenic
effect of diepoxybutane (DEB) used as a specific diag-
nostic marker [7]. This hypersensitivity, apart from being
an indicator of DNA repair deficiency, may reflect the
reduced capacity of FA cells to respond to the OS-
related mechanism of DEB cytotoxicity. In fact, there is
both in vitro and in vivo evidence indicating that FA cells
are in a permanent pro-oxidant state, demonstrated by
oxidative DNA damage, increased lipid peroxidation, free
iron levels, overproduction of reactive oxygen species
(ROS), mitochondrial dysfunction, and glutathione (GSH)
depletion [8, 9]. A recent review summarized the latest
understanding on the roles of FA proteins in modulating
redox functions and the evidence for molecular and clin-
ical involvement of OS in the FA phenotype [10].
Hematological abnormalities occur in virtually all FA
patients, but their progression is quite variable. At birth,
peripheral blood counts can be normal, but bone mar-
row may already be hypoplastic and has a reduced pool
of CD34+ hematopoietic stem cells (HSCs) [11, 12].
Neonatal aplastic anemia in FA has already been de-
scribed [13], although hematopoietic dysfunction may
not be recognized in infancy because of the significant
compensatory mechanisms present in the bone marrow.
One of these compensatory mechanisms is stress
erythropoiesis, a state of hematopoietic emergency in
which the production of erythrocytes is rapidly increased
in response to tissue hypoxia, associated to anemia or
redox imbalance [14]. Importantly, macrocytosis and in-
creased fetal hemoglobin (HbF), by definition the main
indicators of stress erythropoiesis [15, 16], appear among
the first parameters that become altered during
hematological complications in FA. Anemia is usually
the last cytopenia to be expressed.
The significance of RDW and its possible relation to a
stress erythropoiesis or a cellular pro-oxidant state have
never been explored in FA. The aim of the present study
was to analyze the values of RDW in FA and search for a
correlation with the hematological parameters most con-
sistently associated to the FA phenotype. The importance
of RDW as a marker of stress erythropoiesis is explored.
Methods
Subjects
This study does not report on primary research. All clin-
ical data were obtained from protected files resulting from
routine diagnosis and treatment, were processed anonym-
ously and are in accordance with the Helsinki Declaration
of 1975, as revised in 2000. It included 34 patients (16
males and 18 females) referred for confirmation/exclusion
of FA diagnosis based on the DEB test. All patients were
diagnosed as FA (DEB+) with a mean age of 10 years
(Table 1). 24 patients (P1-P24) presented physical abnor-
malities compatible with FA and hematologic abnormal-
ities compatible with BMF; 5 patients (P25-P29) presented
hematologic abnormalities compatible BMF without phys-
ical abnormalities. Five patients (P30-P34) were referred
for being FA siblings/relatives.
Cells and cell cultures
From each patient, heparinized peripheral blood was col-
lected at the time of diagnosis, to perform lymphocyte
cultures for DEB-induced CI determination, according
to a standard protocol [17]. In brief, whole blood
(0.5 ml) was cultured in RPMI medium supplemented
with 15 % FCS and antibiotics. Cultures were stimulated
with phytohemagglutinin (5 μg/ml) and incubated at
37 °C, 5 % CO2, for 72 h. DEB (0.1 μg/ml) was added
24 h after culture initiation. Since DEB is a carcinogen
with unknown risk, the appropriate safety precautions
were taken [18].
Cytogenetic analysis
Cells were harvested after 1 h incubation with colcemid
(4 μg/ml), followed by hypotonic treatment with 75 mM
KCl and fixation in a 1:3 solution of acetic acid:methanol.
Chromosome preparations were performed by the stand-
ard air drying method, and stained with 4 % Giemsa.
Chromosome aberrations were analyzed by two inde-
pendent scorers on 50–100 metaphases from coded slides.
A minimum of 25 metaphases was counted only when the
mitotic index was very low and the rate of CI very high.
Each cell was scored for chromosome number and types
of structural abnormalities. Tri- tetra-radial figures, dicen-
tric and ring chromosomes were scored as rearrangements
and were scored as two breaks. Cells with so much in-
stability that was not possible to count the number of
breaks were classified as pulverized cells. CI was deter-
mined according to the International Fanconi Anemia
Registry (IFAR) protocol [18]; the parameter number
of breaks/cell was selected in this study, once it is
the discriminating one for the FA diagnosis [7].
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Hematological evaluation
For each patient a complete blood count was deter-
mined, for routine purposes, at the time of cytogenetic
evaluation. None of them has been subjected to transfu-
sions previously to this evaluation. The following
hematological parameters were selected for the present
study: red blood cells (RBC) count (×106/μL), hemoglobin
(Hb) level (g/dL), neutrophil (Neut) and platelet (Plt)
counts (×103/μL), mean corpuscular volume (MCV) value
(fL), fetal hemoglobin (HbF) and RDW-CV (coefficient of
Table 1 Physical, hematological and cytogenetic characterization of 34 Fanconi anemia (FA) patients at diagnosis
FA patients (DEB+) Presence (+) or absence (−) of hematological
abnormalities
Presence (+) or absence (−) of congenital
abnormalities
Patient number Gender Age diag brk/cel Thromb Neut Anem ↑HbF Macroc Skin Growth Facies Thumb Urog Heart
1 F 8 15.0 + + + + + - + - - - +
2 M 7 11.3 + + + + + + + - - - -
3 F 5 1.0 + + + + + + + - - - -
4 F 4 6.6 + + + + + + - - + - -
5 F 16 1.5 + + + ND + - + + + - -
6 M 10 7.0 + + +(1) + + + - - + - -
7 M 3 7.6 + - +(1) ND - - - + + + +
8 F 9 6.7 + + +(1) ND + - + - + - -
9 M 2 13.4 + + + ND + - + - + - -
10 F 6 7.2 + + + ND + - - - + + -
11 F 8 4.5 + + + ND + - + + - - -
12 M 1 3.1 + - + + + - + + - - -
13 F 3 4.1 + + + ND + - - + - + -
14 M 8 11.7 + + + + + - + - - - -
15 F 4 2.2 + - +(1) + + - - + - - -
16 F 6 2.1 + + + ND + + - - - - -
17 F 12 1.8 + + + ND - + - - - + -
18 M 12 1.7 + + +(1) ND + + - - - - -
19 F 18 9.1 + + + ND - - + + - - -
20 M 12 1.3 + + + ND - - + - - + -
21 M 3 3.1 + - - + - - - - - + +
22 M 25 1.1 - + - ND + + - - - - -
23 M 1 1.5 - - - + - + - - - - -
24 F 8 5.4 + + +(1) + + + - - - - -
25 M 29 9.7 + + + + + - - - - - -
26 F 21 12.0 + + + + + - - - - - -
27 F 12 8.6 + + + + + - - - - - -
28 M 7 4.4 + + + + - - - - - - -
29 F 17 6.6 + - + ND + - - - - - -
30* M 1 7.5 - + + + - - - + - - -
31* M 4 7.1 - + - - - + + - - + -
32* F 34 7.1 + + + ND - - - - - - -
33* F 10 7.1 - - - ND + - - - - - -
34* M 0 5.0 - + +(2) ND - - - - - - -
FA Fanconi anemia, brk/cel number of DEB (diepoxybutane)-induced breaks per cell; reference values (min-max) for brk/cel in a DEB+ test: 0.96–17.0, ND not
determined * referred for familial study, age diag age, in years, at the time of diagnosis, thromb thrombocytopenia, neut neutropenia, anem anemia, ↑HbF
increased fetal hemoglobin, macroc macrocytosis, skin abnormal skin pigmentation with café au lait spots, growth small stature, facies particular facies, small head
and eyes, thumb thumb abnormalities, urog renal or gonadic abnormalities, heart cardiac abnormalities
(1) normal hemoglobin values, decreased red blood cell counts; (2) normal red blood cell counts, decreased hemoglobin
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Fig. 1 (See legend on next page.)
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variation) values (%). Complete blood counts were per-
formed using the system available in each hospital: Advia
2120 (Siemens) or Cell-Dyn (R) Saphire (TM) (Abbott).
Those systems don’t measure RDW-SD (standard devi-
ation); they only measure RDW-CV.
Normal ranges (minimum and maximal) were estab-
lished according to laboratorial reference values, with
age and gender adjustments [19]. For 3 patients (P9,
P11, P33), with distinct clinical outcomes, a sequential
comparative analysis was performed between RDW and
Hb values, depicted from routine blood counts deter-
mined over 10 years of follow-up (without transfusions
or bone marrow transplant).
Statistical analysis
Statistical analysis was performed using the GraphPad
Prism 5. Normality was assessed by Shapiro-Wilk good-
ness test. Correlation between continuous non-parametric
variables was determined by the Spearman test. Compara-
tive analysis between groups was determined using the
Mann Whitney test.
Results
RDW is increased in most FA patients
Hematological parameters commonly used in the
characterization of FA were depicted from routine
complete blood counts of 34 FA patients, determined
at the time of diagnosis. The results showed that
82 % of the patients had decreased RBC values with a
median = 3.4 × 106/μL (1.9–4.4) (Fig. 1 a), 68 % had
decreased Hb values with a median = 11.1 g/dL (6.9–
14.4) (Fig. 1 b), 79 % had decreased Neut values with
a median = 1.4 × 103/μL (0.4–4.2) (Fig. 1 c), 82 % had
decreased Plt values with a median = 52.0 × 103/μL
(15.0–385.0) (Fig. 1 d) and 68 % had increased MCV
values with a median = 97.5 fL (73.0–118.5) (Fig. 1 e).
HbF was increased in 100 % of the 16 patients so far
evaluated, with a median = 11.3 % (1.9–29.5) (Fig. 1 f).
RDW values depicted from the same complete blood
counts were then evaluated. They were increased in 68 %
of the patients, with a median = 15.0 % (13.0–22.7)
(Fig. 1 g). RDW increase was independent of gender
(p = 0.6838) and presence/absence of congenital ab-
normalities (p = 0.2829), and was not correlated with
age at diagnosis (r = 0.1596, p = 0.3672) nor DEB-
induced CI (r = 0.2795, p = 0.1145).
Increased RDW correlates with anemia, neutropenia and
thrombocytopenia in FA patients
In order to better analyze the clinical significance of the
increased RDW in FA patients, correlations were per-
formed between RDW and the hematological parameters
most relevant for FA characterization. The results
showed that RDW from FA patients had a very strong
(negative) correlation with Hb (r = 0.8502, p < 0.0001)
(Fig. 2 a), a strong (negative) correlation with RBC (r =
0.6943, p < 0.0001) (Fig. 2 b) and a moderate (negative)
correlation with Neut and Plt (r = 0.4976, p = 0.0014 and
r = 0.4560, p = 0.0034 respectively) (Fig. 2 c-d). No sig-
nificant correlations were observed between RDW and
HbF or MCV (p = 0.1229 and p = 0.3214 respectively)
(Fig. 2 e-f ).
Correlation between RDW and Hb during follow-up stud-
ies of FA patients with different clinical progression
The correlation between RDW and Hb was further ex-
plored in sequential hemograms from individual FA pa-
tients with different clinical outcomes, not subjected to
transfusions or bone marrow transplant: a clinically stable
adult patient (P33); a young patient with a previous pro-
gression to BMF that reverted to a stable condition (P11);
a patient with severe BMF since childhood who initiated
androgen treatment (P9) while is waiting for a compatible
bone marrow donor. Sequential RDW and Hb variations,
routinely evaluated during 10 years follow-up, were com-
pared. Patient P33 (Fig. 3 a), who is clinically stable,
showed some anemia events during follow-up, accompan-
ied by proportional increases in RDW values (points 3, 5,
7, 17 and 19 in the x-axis of Fig. 3 a), which then turn to
normal values accompanied by normal Hb levels. Pa-
tient P11 (Fig. 3 b) showed a severe progression to BMF
from 9 to 13 years of age (from points 1 to 16 in the x-
axis of Fig. 3 b) and suddenly a spontaneous improve-
ment occurred, with Hb values increasing till normal
values accompanied by a decrease in RDW values till a
normal range. Patient P9 (Fig. 3 c) presented pancyto-
penia, with anemia, since 1 year of age, accompanied by
increased RDW values. His clinical condition worsened
at 10 years when he started an androgen treatment, with
oxymetholone (OXM) (at point 32 in the x-axis of Fig. 3
c). The treatment improved significantly the Hb levels;
however, RDW values did not decrease to normal
values.
(See figure on previous page.)
Fig. 1 Graphic representation of hematological values from 34 FA patients. Normal ranges with minimum and maximal standard deviation
(−2SD, +2SD) or minimal and maximal percentage (Min, Max) were established according to internal laboratorial reference values, with
age and gender adjustments. Median value (min-max) of this Fanconi anemia (FA) population is indicated for each parameter. a red
blood cells (RBC) counts (x106/µL). b hemoglobin (Hb) values (%). c neutrophil (Neut) counts (x103/µL). d platelet (Plt) counts (x103/µL).
e mean corpuscular volume (MCV) value (fL). f fetal hemoglobin (HbF) values (%). g red cell distribution width (RDW) values (%)
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Discussion
Clinical relevance of increased RDW in FA patients
RDW is a simple parameter that reflects anisocytosis
and is traditionally used in the differential diagnosis of
anemia. However, increased RDW is also associated to a
great number of diseases and, most importantly, associ-
ated with overall mortality in the general population [1].
More recently, the prognostic value of increased RDW
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Fig. 2 Correlation between RDW hematological parameters most relevant for FA characterization. Red cell distribution width (RDW) values
and hematological parameters most relevant for Fanconi anemia (FA) characterization were depicted from routine complete blood counts
of 34 FA patients. All values are provided with standard measurement units; p-values >0.05 are not significant, p-values <0.01 are
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in coronary artery disease was reviewed, the negative
prognostic effects being attributed to the adverse effects
of independent risk factors, including OS [20]. Early
studies by Nordenson and Joenje established that FA
cells present excess oxygen toxicity that leads to OS
damage [21, 22]. Since then, several research groups
found evidence that FA is characterized by abnormal ac-
cumulation of ROS and dysfunctional response to OS
[10, 23–33]. Nevertheless, there are no reports in the lit-
erature about the importance of RDW in the FA
P33
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Fig. 3 Correlation between RDW and Hb values in sequential follow-up hemograms from 3 FA patients. Red cell distribution width (RDW) values
and hemoglobin (Hb) values were depicted from sequential hemograms, routinely evaluated during 10 years follow-up, of 3 Fanconi anemia (FA)
patients with different clinical outcomes: an adult patient clinically stable (P32); a young patient with a previous progression to bone marrow
failure (BMF) that reverted to a stable condition (P9); a patient with severe BMF since childhood who initiated androgen treatment after 10 years
follow-up (P7). All values are provided with standard measurement units
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phenotype. In the present study we clearly showed that
RDW is significantly increased in most FA patients and
is associated with severity of FA disease, i.e., correlated
with thrombocytopenia, neutropenia and, most import-
ant, highly correlated with anemia.
Hematopoiesis in FA is impaired from the earliest
stages of embryonic development [34], and there is a
body of evidence supporting the role of dysfunctional
HSC biology in the etiology of the disease [35]. Progres-
sion to BMF has been considered to be caused by two
different mechanisms: the accumulation of OS-induced
DNA damage along mitotic divisions, by deficiency in
the FA/BRCA repair pathway, resulting in p53 activation
and apoptosis of the hematopoietic progenitors [36, 37]
and overproduction of inhibitory cytokines, which can
degrade bone marrow [38], leading to impaired erythro-
poiesis and RBC degradation. In a recent work a novel
connection was established between stress
hematopoiesis and the occurrence of DNA damage and
functional decline in HSCs: it was shown that DNA
damage can be a consequence of the exit of HSCs from
their homeostatic quiescent state in response to physio-
logical stress, such as infection [39]. Using a Fanca−/−
mice model, it was shown that repeated activation of
HSCs out of their dormant state leads to a complete col-
lapse of the hematopoietic system, which phenocopied
the highly penetrant BMF seen in FA patients. All
these studies support the hypothesis of a progressive
hematopoietic impairment in FA associated with a de-
creased capacity of the bone marrow to send mature
RBC to the periphery, which may lead to RDW
increment.
In summary, we showed for the first time that in-
creased RDW is an important clinical marker in FA,
with the advantage that this value is easily determined as
a part of the standard cell blood count without add-
itional costs. We suggest that increased RDW in FA may
be, like in other OS-related disorders, a consequence of
deregulation of RBC homeostasis, involving both im-
paired erythropoiesis and RBC degradation.
RDW as a marker of stress erythropoiesis
At birth FA patients have normal blood counts, although
the bone marrow is hypoplastic and deficient in CD34+
HSCs long before peripheral blood abnormalities appear
[11, 12]. Macrocytosis and increased HbF, which are
considered markers of stress erythropoiesis [16], are gen-
erally the first manifestations to be found in FA periph-
eral blood cells. Interestingly, in our FA population these
two parameters were not correlated with RDW. We pos-
tulate that, while macrocytosis and increased HbF reflect
a stress erythropoiesis that is responding to bone mar-
row impairment, increased RDW may reflect a stress
erythropoiesis that is responding to a progressive
shortened RBC survival at the periphery, which must be
compensated by a constant RBC turnover. Therefore, we
propose that RDW reflects the need for a recruitment of
HSCs to the periphery. This hypothesis is supported by
the work of Rodriguez A, Vadillo E, Gonzalez M, Flores
P, Sosa D, Torres L, Garcia de Teresa B, Mayani H,
Pelayo R and Frias S (unpublished observations, pre-
sented at the 26th Annual Fanconi Anemia Research
Fund Scientific Symposium, Additional file 1) where it
was shown the presence of circulating CD34+ cells and
elevated G-CSF levels in the peripheral blood of FA indi-
viduals. They suggested that elevated production of G-
CSF and the pro-inflammatory bone marrow microenvir-
onment could be responsible for the stress erythropoi-
esis with mobilization of CD34+ precursor cells to the
periphery. According to the present study, we suggest
that RDW increment may be the result of a stress
erythropoiesis that is responding to an OS-related de-
regulation of RBC homeostasis and RBC degradation at
the periphery, which leads to a mobilization of more im-
mature erythropoietic cells from bone marrow. In ac-
cordance, cytoskeleton-dependent alterations were
already observed in FA RBC, leading to cell shrinking
and blebbing, being hypothesized that these changes
may be the result of OS imbalance that leads to alter-
ations in RBC plasticity and deformation-associated
functions [40].
RDW as a marker of hematological disease progression
To better understand if RDW variation can be an im-
portant marker during progression of hematological dis-
ease, in the present study we evaluated the correlation
between RDW and Hb values, obtained from sequential
hemograms over 10 years of follow-up, from 3 FA pa-
tients with different clinical progressions, not subjected
to transfusions or bone marrow transplant. In general,
whenever RDW was among normal ranges Hb was also
among normal values. RDW increment was systematic-
ally correlated with Hb decrease. A graphic model for
controlling adverse outcome is proposed, based on the
position of sequential RDW and Hb values relatively to
reference normal lines (red line for +2SD RDW values
and blue line for -2SD Hb values) (Fig. 3). While RDW
and Hb values are inside the two reference lines the
hematological situation is stable. Whenever RDW and
Hb values are outside the two reference lines, the clin-
ical situation worsens. In fact, the adult patient P33, who
is now clinically stable, presents RDW and Hb values in-
side the two reference lines, although during the 10 years
follow-up the patient showed some anemia events ac-
companied by proportional increases in RDW values
(values outside the two reference lines). Patient P11 is
also stable at present, with RDW and Hb values inside
the two reference lines, but after a sudden recovery from
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a severe situation of BMF, where RDW and Hb values
were clearly outside the two reference lines. In fact, at
8 years she presented an unexplained progressive wors-
ening of hematological disease, prolonged for about four
years, after which, and in the absence of any treatment,
a spontaneous recovery occurred. Sequential evaluation
of chromosome instability revealed a reduction in the
number of DEB-induced breaks, although not sufficient
to be classified as a somatic mosaicism [41], which could
explain this new clinical situation (Porto B, personal
communication). Patient P9, with a severe condition of
BMF since childhood, presented during 10 years follow-
up RDW and Hb values always outside the two reference
lines, with a progressive detachment between the two
values. When the patient started OXM treatment, Hb
immediately increased up to normal values. However,
Hb increase was not accompanied by RDW decrease.
We hypothesize that erythropoiesis, for some reason,
continues to be stressed. Androgens are widely used for
FA treatment, but their mode of action is not completely
understood. In a recent study [42] aged Fancd2−/− mice
were used to assess the therapeutic efficacy of OXM.
Chronic OXM treatment significantly improved
hematological parameters, decreasing macrocytosis and
pancytopenia, and stimulated the proliferation of
hematopoietic stem and progenitor cells. However, com-
petitive repopulation assays demonstrated that this ther-
apy eventually results in stem cell exhaustion, which
may have direct clinical implications for the treatment of
BMF. In agreement with these results, we hypothesize
that, in the case of patient P9, the fact that Hb demand
is not accompanied by RDW decrease may probably lead
to a risk of HSCs exhaustion in the long term.
Our study has two main limitations: the RDW value,
per se, is not a diagnostic marker, because some patients,
with a mild hematological disease, can still have normal
RDW values. Therefore, its main importance is related
to the progression of hematological disease, as shown by
the present results. Additionally, as the follow-up data
only relates to three patients, the hypothesis regarding
the use of RDW to predict severity of disease and ad-
verse outcomes must be evaluated in a future work, with
a higher number of patients included.
Conclusion
In conclusion, the present study provides an important
and novel clinical finding that may have importance for
the follow-up of FA patients: it was shown, for the first
time, that RDW is increased in FA patients and this in-
crement is related with progression of hematological dis-
ease, in particular progression to anemia. It is suggested
that increased RDW can be a novel marker of stress
erythropoiesis in FA.
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